Ted Buchan & CO Dexcom Inc Transaction History

Ted Buchan & CO

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 Sep 06, 2024	SELL	$114.22 - $140.1 $185,150 - $227,102	-1,621 Reduced 32.04%	3,439 $477 Million
Q4 2023 Sep 06, 2024	BUY	$75.49 - $124.16 $21,665 - $35,633	287 Added 6.01%	5,060 $628 Million
Q3 2023 Sep 06, 2024	BUY	$86.06 - $137.93 $1,032 - $1,655	12 Added 0.25%	4,773 $445 Million
Q2 2023 Sep 06, 2024	SELL	$112.47 - $130.98 $31,941 - $37,198	-284 Reduced 5.63%	4,761 $612 Million
Q1 2023 Sep 06, 2024	SELL	$104.0 - $122.92 $6,760 - $7,989	-65 Reduced 1.27%	5,045 $586 Million
Q4 2022 Sep 06, 2024	BUY	$84.98 - $122.67 $434,247 - $626,843	5,110 New	5,110 $579 Million

1,072

339M

6.74M

6.33M

Ticker DXCM
Exchange NASDAQ
Sector Healthcare
Industry Medical Devices
Shares Outstandng 386,257,984
Market Cap $34.4B
Description
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM ...

Get notified when there are updates to the investment portfolio of Ted Buchan & CO, based on Form 13F filings with the SEC.

Stay updated on Ted Buchan & CO with notifications on news.